drugset
drugset / Trial / NCT03650491

A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT03650491 ↗

Phase 1 Completed 31 enrolled Fortis Therapeutics, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

This study will test the safety and efficacy of FOR46 given every 21 days to patients with relapsed or refractory multiple myeloma. The name of the study drug involved in this study is: FOR46 for Injection

Timeline

Start
2019-04-03
Primary completion
2022-01-31
Completion
2022-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject FOR46 Other / unclassified — Intravenous

Indications

plasma cell myeloma